Daily Archive: Monday, April 24, 2017

Biotech Stocks Facing FDA Decision In May

The month of April witnessed the FDA approving the first ever drug for tardive dyskinesia, a neurological disorder characterized by involuntary muscle movements. The first to market tardive dyskinesia drug is Neurocrine Biosciences Inc.’s (NBIX) Ingrezza, and is expected to be launched on May 1, 2017. Not far behind, waiting to enter this niche market

Gateway Expands National Reach by Opening New Treatment Center in New Jersey

“Substance use continues to be a critical problem for the nation, and one that requires a unique approach to solve, especially among those that may not be ready for treatment,” said Dr. Thomas Britton, president and CEO of Gateway Foundation. Chicago, IL (PRWEB) April 24, 2017 Gateway Foundation, a leading non-profit provider of alcohol

Game Changing 100% Recyclable and Sustainable Outdoor Collection

Tahoe Brightens Any Space by Adding Visual Appeal Indoors and Out with Sustainable Qualities “Whether it’s reflecting quietly in a modern museum or harnessing the power of the outdoors, Tahoe is multi-functional,” Nora Fenlon, VP of via seating. Sparks, NV (PRWEB) April 21, 2017 Nestled in the heart of the Sierra Nevada Mountain range